Clone:
REA477
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC
Alternative names:
MerTK, Eyk, Nyk, nmf12, c-Mer

Extended validation for Mer Antibody, anti-mouse, REAfinity™

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REA477
DS5MMER-
2B10C42-
108929++
Cells were incubated with an excess of purified unconjugated Mer (REA477) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for Mer. Thioglycollate-elicited peritoneal exudate cells from C57BL/6 mice were stained with Mer antibodies and with a suitable counterstaining. As a control, Mer antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for Mer. Thioglycollate-elicited peritoneal exudate cells from C57BL/6 mice were stained with Mer antibodies and with a suitable counterstaining. As a control, Mer antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for Mer. Thioglycollate-elicited peritoneal exudate cells from C57BL/6 mice were stained with Mer antibodies and with a suitable counterstaining. As a control, Mer antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for Mer. Thioglycollate-elicited peritoneal exudate cells from C57BL/6 mice were stained with Mer antibodies and with a suitable counterstaining. As a control, Mer antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for Mer. Thioglycollate-elicited peritoneal exudate cells from C57BL/6 mice were stained with Mer antibodies and with a suitable counterstaining. As a control, Mer antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using Mer (REA477). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using Mer (REA477). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using Mer (REA477). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for Mer Antibody, anti-mouse, REAfinity™

Overview

Clone REA477 recognizes the mouse Mer antigen, a single-pass type I membrane protein, which is also known as proto-oncogene c-Mer or receptor tyrosine kinase MerTK. Mer is a receptor tyrosine kinase of the TAM (Tyro3, Axl, MERTK) family that transduces signals from the extracellular matrix into the cytoplasm by binding to several ligands including LGALS3, TUB, TULP1, or GAS6. It regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells. Mer is overexpressed or ectopically expressed in a wide variety of cancers, including leukemia, non-small cell lung cancer, glioblastoma, melanoma, prostate cancer, breast cancer, colon cancer, gastric cancer, pituitary adenomas, and rhabdomyosarcomas, potentially resulting in the activation of several canonical oncogenic signaling pathways. These include the mitogen-activated protein kinase and phosphoinositide 3-kinase pathways, as well as regulation of signal transducer and activator of transcription family members, migration-associated proteins including the focal adhesion kinase and myosin light chain 2, and prosurvival proteins such as survivin and Bcl-2. In neoplastic cells, these signaling events result in functional phenotypes such as decreased apoptosis, increased migration, chemoresistance, increased colony formation, and increased tumor formation in murine models. Conversely, Mer inhibition by genetic or pharmacologic means can reverse these pro-oncogenic phenotypes.
Additional information: Clone REA477 displays negligible binding to Fc receptors.

Alternative names

MerTK, Eyk, Nyk, nmf12, c-Mer

Detailed product information

Technical specifications

CloneREA477
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody, human IgG1
Hostcell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Speciesmouse
AntigenMer
Alternative names of antigenMerTK, Eyk, Nyk, nmf12, c-Mer
Molecular mass of antigen [kDa]108
Distribution of antigenubiquitous
Entrez Gene ID17289
RRIDAB_2652854, AB_2652855, AB_2652856, AB_2652857

References for Mer Antibody, anti-mouse, REAfinity™

Publications

  1. Cook, R. S. et al. (2013) MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis. J. Clin. Invest. 123(8): 3231-3242
  2. Graham, D. K. et al. (1995) Cloning and developmental expression analysis of the murine c-mer tyrosine kinase. Oncogene 10(12): 2349-2359

Related products for
Mer Antibody, anti-mouse, REAfinity™

2 products available